Softwr

Healthcare · head to head

Lunit vs Woebot Health

Lunit logo

Lunit

Healthcare

FDA cleared and CE marked AI for mammography, tomosynthesis and chest radiography

From
On request
Rated
-
Full reviewWebsite
Woebot Health logo

Woebot Health

Healthcare

Conversational CBT chatbot that withdrew from consumer distribution and now sells only to payers and providers

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Lunit the regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.; Woebot Health the company withdrew its consumer app in June 2025 after concluding FDA marketing authorisation was not achievable at acceptable cost, which is a plain signal about both regulatory position and commercial durability.
  • They diverge on capability: Lunit covers Lunit INSIGHT MMG, Woebot Health covers Scripted CBT dialogue.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Lunit and Woebot Health actually diverge.

Attributes where Lunit and Woebot Health differ
AttributeLunitWoebot Health
PlatformsWebiOS, Android, Web

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Lunit

  • Lunit INSIGHT MMG
  • Lunit INSIGHT DBT
  • Lunit INSIGHT CXR
  • Volpara density assessment
  • Volpara RiskPathways
  • Volpara dose tracking
  • PACS and mammography workstation integration

Only in Woebot Health

  • Scripted CBT dialogue
  • Mood tracking
  • Crisis routing
  • Between-session support
  • Payer deployment
  • Provider copilot positioning
  • Research licensing
  • Population reporting

What people use each for

The jobs each tool is most often brought in to do.

Lunit

  • A national breast screening programme evaluating AI as a second reader to reduce double reading workload where two human readers are currently mandatednot Woebot Health
  • A breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on DBT specificallynot Woebot Health
  • An American breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what Volpara is bought fornot Woebot Health
  • A tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise filmsnot Woebot Health

Woebot Health

  • A health plan wanting a low intensity behavioural health option for members on a waiting list for therapynot Lunit
  • A provider organisation offering structured between-session CBT practice to patients already in treatmentnot Lunit
  • A research group running a trial that needs a clinically scripted rather than generative conversational agent for safety reasonsnot Lunit
  • A payer targeting a specific population such as postpartum members where scripted CBT content already existsnot Lunit

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Lunit

  • The regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • Detection AI changes recall rates in screening, and the downstream cost of additional diagnostic workup lands on the programme rather than on the software budget, which is the cost most screening business cases omit.
  • Performance is sensitive to the mammography vendor and acquisition protocol, so published results from a Hologic estate do not transfer to a GE or Siemens estate without local validation the buyer must fund.
  • MMG, DBT and CXR are licensed separately and Volpara modules are separate again, so a breast centre wanting detection, density and risk pathways is assembling four line items rather than buying one product.
  • Using AI as a replacement for one of two human readers is a workforce and liability decision that regulators and professional bodies treat differently in each country, so the saving that justifies the purchase may not be permitted where you operate.

Woebot Health

  • The company withdrew its consumer app in June 2025 after concluding FDA marketing authorisation was not achievable at acceptable cost, which is a plain signal about both regulatory position and commercial durability.
  • It is not an FDA cleared treatment for any indication, so it cannot be positioned to members as therapy and cannot substitute for a covered behavioural health benefit.
  • The scripted, non-generative design that makes it safe also makes it feel rigid next to current conversational AI, and engagement drops off quickly once users hit the edges of the script.
  • Published evidence is short-horizon symptom change in selected populations, mostly young adults, with little evidence of durable benefit or effect at whole-population scale.
  • With consumer distribution gone, the remaining business depends on a small number of payer and provider contracts, so a buyer should assume real vendor continuity risk over a multi-year term.

Pricing, plan by plan

Lunit

On request
  • Lunit INSIGHT$undefined/year
    • Priced per study or per annual examination volume by product
    • MMG, DBT and CXR licensed separately
    • Volpara density and RiskPathways modules quoted separately

Woebot Health

On request
  • Woebot for payers and providers$undefined/year
    • Contracted per member per month or as a population licence
    • Sold to health plans and provider organisations, not to employers or individuals
    • No consumer purchase route since the app closed in June 2025

Which should you pick?

Choose Lunit if

  • You need lunit insight mmg.
  • You also want lunit insight dbt.
Lunit review

Choose Woebot Health if

  • You need scripted cbt dialogue.
  • You work on iOS, Android, Web.
  • You also want mood tracking.
Woebot Health review

Questions people ask

Is Lunit or Woebot Health better?
Neither clearly leads. Lunit starts at On request and Woebot Health at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Lunit or Woebot Health?
Lunit starts at On request and Woebot Health at On request.
Does Lunit or Woebot Health run on more platforms?
Lunit runs on Web. Woebot Health runs on iOS, Android, Web.
What is Lunit best used for?
Lunit is most often used for a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated, a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically, an american breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what volpara is bought for, a tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise films. Of those, a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated and a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically are not what Woebot Health is typically brought in for.
What can Lunit do that Woebot Health cannot?
Lunit covers Lunit INSIGHT MMG, Lunit INSIGHT DBT, Lunit INSIGHT CXR, Volpara density assessment. Woebot Health covers Scripted CBT dialogue, Mood tracking, Crisis routing, Between-session support.

Answered from the vendors’ own pages

Lunit: Is Lunit FDA cleared?

Yes for specific products. INSIGHT MMG, INSIGHT DBT and INSIGHT CXR Triage hold FDA 510(k) clearances. INSIGHT Risk, the five year risk prediction model, has been filed but was not cleared at the time of writing.

Woebot Health: Is Woebot still available?

Not to consumers. The consumer app closed in June 2025. The company continues to offer the product to payers, providers and researchers.

Lunit: Can Lunit replace a second human reader in screening?

That depends entirely on your jurisdiction and professional body guidance, not on the software. The CE mark permits clinical use; it does not authorise a workforce model.

Woebot Health: Is it FDA cleared?

No. It held Breakthrough Device designation but never obtained marketing authorisation, and the founder cited the cost of that pathway as the reason for closing the consumer app.

Lunit: What did the Volpara acquisition add?

Volumetric breast density measurement, dose tracking and RiskPathways high risk programme management, which are the things American breast centres buy for density notification compliance rather than for detection.

Woebot Health: Is it generative AI?

Historically no. The dialogue is clinician-written and rule-based, a deliberate safety choice that limits how naturally it converses.

Lunit: Is pricing published?

No. It is quoted per study or per annual volume, by product, with on premises and cloud priced differently.

Woebot Health: What does the evidence show?

Randomised studies reported reduced depressive symptoms over short periods in selected populations, notably young adults. That is symptom change in a trial, not demonstrated population outcomes.

Share

Related pages

More on Lunit

More on Woebot Health

Keep looking

Other head to heads